Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,411,012
  • Shares Outstanding, K 60,140
  • Annual Sales, $ 77,430 K
  • Annual Income, $ -184,680 K
  • 60-Month Beta 1.90
  • Price/Sales 31.33
  • Price/Cash Flow N/A
  • Price/Book 14.04
Trade RYTM with:

Options Overview Details

View History
  • Implied Volatility 68.03% ( -2.98%)
  • Historical Volatility 47.78%
  • IV Percentile 60%
  • IV Rank 43.46%
  • IV High 87.74% on 07/11/23
  • IV Low 52.89% on 01/05/24
  • Put/Call Vol Ratio 1.33
  • Today's Volume 7
  • Volume Avg (30-Day) 287
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 14,960
  • Open Int (30-Day) 11,353

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -2.12
  • Number of Estimates 8
  • High Estimate -0.59
  • Low Estimate -2.39
  • Prior Year -0.92
  • Growth Rate Est. (year over year) -130.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.65 +2.30%
on 03/20/24
43.68 -11.81%
on 04/09/24
-1.48 (-3.70%)
since 03/15/24
3-Month
37.65 +2.30%
on 03/20/24
52.57 -26.73%
on 02/12/24
-2.07 (-5.10%)
since 01/16/24
52-Week
15.50 +148.51%
on 07/06/23
52.57 -26.73%
on 02/12/24
+19.12 (+98.56%)
since 04/14/23

Most Recent Stories

More News
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

PTN : 1.8700 (+2.75%)
RYTM : 38.52 (-3.92%)
VKTX : 67.95 (+1.49%)
GPCR : 37.82 (+0.45%)
NVO : 123.45 (-0.36%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...

PTN : 1.8700 (+2.75%)
RYTM : 38.52 (-3.92%)
VKTX : 67.95 (+1.49%)
GPCR : 37.82 (+0.45%)
NVO : 123.45 (-0.36%)
What Will Amgen Buy Next?

The biotech could pursue these two budget-friendly targets.

REGN : 894.14 (-0.49%)
AMGN : 265.64 (+0.05%)
HZNP : 116.30 (+0.04%)
NTLA : 21.81 (-4.84%)
RYTM : 38.52 (-3.92%)
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -29.58% and 2.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

RYTM : 38.52 (-3.92%)
RXDX : 199.92 (+0.09%)
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FATE : 5.38 (-4.61%)
RYTM : 38.52 (-3.92%)
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 8.54% and 24.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

RYTM : 38.52 (-3.92%)
VBIV : 0.6200 (+6.90%)
3 Breakout Growth Stocks to Buy for the Long Haul

These three have had big-time share gains backed up by breakthrough science.

BLTE : 35.88 (-1.97%)
TMDX : 93.31 (+1.62%)
RYTM : 38.52 (-3.92%)
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Lags Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 21.78% and 20.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

RYTM : 38.52 (-3.92%)
AFMD : 5.37 (-2.19%)
Earnings Preview: Solid Biosciences Inc. (SLDB) Q3 Earnings Expected to Decline

Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SLDB : 9.82 (-1.80%)
RYTM : 38.52 (-3.92%)
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q3 Earnings Expected to Decline

Rhythm Pharmaceuticals, Inc. (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RYTM : 38.52 (-3.92%)
SGEN : 228.74 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 41.22
2nd Resistance Point 40.67
1st Resistance Point 39.60
Last Price 38.52
1st Support Level 37.98
2nd Support Level 37.43
3rd Support Level 36.36

See More

52-Week High 52.57
Last Price 38.52
Fibonacci 61.8% 38.41
Fibonacci 50% 34.04
Fibonacci 38.2% 29.66
52-Week Low 15.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar